Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
Nike
NKE
|
+$631M |
| 2 |
PNC Financial Services
PNC
|
+$614M |
| 3 |
XYZ
Block, Inc.
XYZ
|
+$328M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
+$275M |
| 5 |
FedEx
FDX
|
+$236M |
Top Sells
| 1 |
Apple
AAPL
|
+$1.16B |
| 2 |
Meta Platforms (Facebook)
META
|
+$595M |
| 3 |
AbbVie
ABBV
|
+$489M |
| 4 |
Crown Castle
CCI
|
+$326M |
| 5 |
McDonald's
MCD
|
+$325M |
Sector Composition
| 1 | Technology | 20.85% |
| 2 | Consumer Discretionary | 16.57% |
| 3 | Financials | 13.84% |
| 4 | Healthcare | 12.56% |
| 5 | Communication Services | 11.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
Spyre Therapeutics
SYRE
$964M
| $14.9M | 0.01% |
60,204
+4,466
| +8% | +$1.11M |
|
427
Ocular Therapeutix
OCUL
$2.24B
| $14.9M | 0.01% |
2,292,752
+297,984
| +15% | +$1.94M |
|
428
Alcoa
AA
$8.6B
| $14.9M | 0.01% |
331,887
-222,798
| -40% | -$10M |
|
429
Constellium
CSTM
$2.08B
| $14.9M | 0.01% |
1,373,661
-425,738
| -24% | -$4.62M |
|
430
First Bancorp
FBNC
$2.28B
| $14.6M | 0.01% |
410,469
+317,529
| +342% | +$11.3M |
|
431
Range Resources
RRC
$8.44B
| $14.6M | 0.01% |
1,005,885
-74,862
| -7% | -$1.09M |
|
432
Freeport-McMoran
FCX
$64.7B
| $14.4M | 0.01% |
821,814
-293,878
| -26% | -$5.16M |
|
433
Acadia Healthcare
ACHC
$2.03B
| $14.1M | 0.01% |
360,971
-498,389
| -58% | -$19.5M |
|
|
NBLX
434
DELISTED
Noble Midstream Partners LP
NBLX
| $13.6M | 0.01% |
290,653
+8,185
| +3% | +$382K |
|
|
AIMT
435
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $13.4M | 0.01% |
+421,866
| New | +$13.4M |
|
436
Kinder Morgan
KMI
$61.5B
| $13.3M | 0.01% |
883,136
+17,998
| +2% | +$271K |
|
437
Chemours
CC
$2.47B
| $13.1M | 0.01% |
269,454
-43,037
| -14% | -$2.1M |
|
|
FTSI
438
DELISTED
FTS International, Inc. Common Stock
FTSI
| $12.7M | 0.01% |
+34,443
| New | +$12.7M |
|
|
DBD
439
DELISTED
Diebold Nixdorf Incorporated
DBD
| $12.6M | 0.01% |
818,207
-492,802
| -38% | -$7.59M |
|
440
Diageo
DEO
$57B
| $12.4M | 0.01% |
91,511
-27,873
| -23% | -$3.77M |
|
441
Huron Consulting
HURN
$2.44B
| $12.4M | 0.01% |
325,014
+84,253
| +35% | +$3.21M |
|
442
Philips
PHG
$26.9B
| $11.9M | 0.01% |
395,847
-130,912
| -25% | -$3.95M |
|
443
Cardlytics
CDLX
$58.6M
| $11.9M | 0.01% |
+811,285
| New | +$11.9M |
|
444
Nutrien
NTR
$27.7B
| $11.8M | 0.01% |
+248,807
| New | +$11.8M |
|
445
Eastman Chemical
EMN
$7.71B
| $11.5M | 0.01% |
108,880
-35,397
| -25% | -$3.74M |
|
|
AM
446
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
| $11.3M | 0.01% |
437,165
-1,228
| -0.3% | -$31.8K |
|
|
NUVA
447
DELISTED
NuVasive, Inc.
NUVA
| $10.9M | 0.01% |
208,038
+32,060
| +18% | +$1.67M |
|
|
SEI
448
Solaris Energy Infrastructure, Inc.
SEI
$1.36B
| $10.6M | 0.01% |
639,218
-182,589
| -22% | -$3.02M |
|
|
CIM
449
Chimera Investment
CIM
$1.16B
| $10.5M | 0.01% |
201,432
| – | – |
|
450
Box
BOX
$4.75B
| $10.5M | 0.01% |
+509,709
| New | +$10.5M |
|